Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
November 4, 2024
Dear Ambry Clients, Providers, Patients and Partners,
On the heels of celebrating Ambry’s 25th Anniversary as a clinical genomics innovator and one of the country’s most trusted laboratory service providers, I am excited to share a new chapter in Ambry’s story. We have entered into a definitive agreement to be acquired by Tempus AI, a company advancing precision medicine through the practical application of artificial intelligence in healthcare. We anticipate the acquisition to officially close in the first quarter of 2025 and look forward to empowering our shared goal of improving patient outcomes.
My use of the phrase ‘new chapter’ in Ambry’s story is intentional. This is because Ambry will operate as a wholly owned subsidiary of Tempus and will continue to provide best-in-class clinical service from our team of committed professionals, all under the Ambry brand. In fact, I’d like to point out several areas that will not change:
• The full menu of testing services and programs provided to you from Ambry will continue uninterrupted.
• You will be supported by the same professionals at Ambry as you have in the past because our people are being retained.
• There are no changes in the ordering or billing process, and we will continue to operate from our current offices and our laboratory in Aliso Viejo, CA.
Our business continuity speaks to the value that we have created at Ambry. Over the last few years, while other laboratories in our industry suffered from challenging market conditions, Ambry experienced record growth due to our focused initiatives in operational excellence, fiscal responsibility, and strategic portfolio management. We have remained true to our legacy of innovation with the launch this year of ExomeReveal™, the launch of our enhanced hereditary cancer menu updates, and in our research collaborations resulting in prestigious peer-reviewed publications.
As a result of these efforts, Ambry has achieved a leading position in the industry, but we recognize that to continue our growth trajectory and deliver on the many patient-first initiatives in our pipeline, we need to be part of a larger, like-minded organization. After an extensive search and consideration of suitors, we are thrilled to be joining Tempus. Our collaboration delivering paired germline and somatic testing services for medical oncologists over the past year provided a unique insight to the synergies between our companies. Among the most important are company culture, focus on innovation, and passion for finding answers to improve patient outcomes.
I have no doubt that the acquisition of Ambry Genetics by Tempus will be an industry-changing event. We will be able to bring Ambry’s 25-year history of leadership in variant interpretation together with Tempus’ multimodal data and robust analytical systems to drive new insights for diagnosing and treating patients. These insights may help life-altering healthcare decisions for those who are not simply patients, but also our friends, family and loved ones.
Sincerely,
Tom Schoenherr
Chief Executive Officer
Ambry Genetics translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Contacts
For Ambry Genetics
gwen@gwengordonpr.com